Macrocyclics

Macrocyclics, Inc., established in 1995 and headquartered in Plano, Texas, is a Contract Development and Manufacturing Organization (CDMO) focused on the early phases of pharmaceutical products. As a subsidiary of Orano Med, a clinical stage radiopharmaceutical company pioneering 212Pb, Macrocyclics has become a key player in supplying high-quality chelating agents to the global radiopharmaceutical industry. The company operates from its facility in Plano, encompassing 20,000 sqft of wet chemistry labs equipped for bench-top and sub-pilot scale manufacturing. With the incorporation of two controlled Good Manufacturing Practice (GMP) suites and the commissioning of the Plano facility in 2016, Macrocyclics demonstrates a commitment to maintaining cutting-edge infrastructure.

www.marcocyclics.com